ScoreHaematology
DIPSS and DIPSS-plus in primary myelofibrosis
Estimates risk and median survival in primary myelofibrosis at any time during the disease course.
Updated 30 October 2026
When to use it
Primary myelofibrosis, at diagnosis or during follow-up, to assess prognosis and eligibility for allogeneic transplant.
What it needs
- Age > 65 years
- Haemoglobin < 10 g/dL
- White cells > 25 × 10⁹/L
- Peripheral blood blasts ≥ 1 %
- Constitutional symptoms (weight loss > 10 % in 6 months, night sweats, fever > 37.5 °C)
- Platelets < 100 × 10⁹/L
- Red cell transfusion dependence
- Unfavourable karyotype
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | Low risk (median not reached) |
| 1–2 | Intermediate-1 risk (median ≈ 14 years) |
| 3–4 | Intermediate-2 risk (median ≈ 4 years) |
| ≥ 5 | High risk (median ≈ 1.5 years) |
In the app it also calculates: DIPSS-plus score.
Practical tip
Unlike the IPSS, the DIPSS is “dynamic”: it can be recalculated when new factors appear during follow-up.
3 more practical tips in the app.
Reference
- Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
- Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
